An Explorative Study Of The Tolerability Of SU011248 In Combination With Docetaxel And Trastuzumab As First-Line Treatment In Patients With Breast Cancer Over-Expressing HER-2.

Trial Profile

An Explorative Study Of The Tolerability Of SU011248 In Combination With Docetaxel And Trastuzumab As First-Line Treatment In Patients With Breast Cancer Over-Expressing HER-2.

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Aug 2016

At a glance

  • Drugs Sunitinib (Primary) ; Docetaxel; Trastuzumab
  • Indications Advanced breast cancer
  • Focus Adverse reactions
  • Sponsors Pfizer
  • Most Recent Events

    • 01 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 13 Aug 2011 Planned End Date changed from 1 Aug 2011 to 1 Sep 2011 as reported by ClinicalTrials.gov.
    • 07 May 2011 Planned End Date changed from 1 Mar 2011 to 1 Aug 2011.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top